Aprea Therapeutics, Inc.
A complete Wall Street Score is unavailable because required model components are missing. Missing model components: debt, revenue, financial, Buffett-style model component. These are scoring components, not a claim that the company has no assets or earnings. Missing inputs are not zero and do not by themselves make this a weak company. Available financial statements and source-backed research remain visible.
Severe listing-compliance risk
The share price is below $1 and the stored reverse-split/listing-risk level is HIGH. No verified reverse-split authorization or announced reverse split is currently recorded. This is a risk signal, not confirmation that Nasdaq has issued a deficiency notice.
APRE · Price history
Price at last available close
$0.51
−$0.24 (-31.76%) 1M
2026-10-27
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Aprea Therapeutics, Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 13, 2026. A research update is not a new financial filing.
Who they are
Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The company's primary drug candidate, ATRN-119, is an oral ATR inhibitor currently undergoing Phase 1/2a clinical trials for patients with advanced solid tumors.
How they make money
Aprea Therapeutics is a clinical-stage biopharmaceutical company that does not currently generate product revenue. Its business model relies on raising capital through equity offerings and potential future licensing or collaboration agreements to fund the research and development of its pipeline of small molecule cancer therapeutics.
Products & services
The company is developing a pipeline of precision oncology therapeutics, primarily focusing on synthetic lethality, including its lead clinical-stage candidate APR-1051, a WEE1 kinase inhibitor, and ATRN-119 (Mosipasertib), an ATR kinase inhibitor.
Brands & revenue mix
Lead clinical-stage WEE1 kinase inhibitor candidate.
Separate brand revenue is not available in this research.Source
ATR kinase inhibitor candidate.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
- Clinical trial patientsSource
Customer concentration
No quantified customer-concentration disclosure is available in the current saved research.
Suppliers, materials & equipment
- Contract Research Organizations (CROs) — The company relies on various unnamed third-party CROs to conduct its clinical trials and manage data collection.Source
- Contract Manufacturing Organizations (CMOs) — The company utilizes unnamed third-party CMOs for the manufacturing of its drug candidates for clinical use.Source
Competitors
Strengths
- Focused pipeline of internally discovered synthetic lethality-based cancer therapeuticsSource
Sources
Company-specific research
Questions worth answering for APRE
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •How long can APRE fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •How is APRE likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •What specifically needs to improve for APRE to reach sustainable profitability?
- •What future growth or profitability would be needed to justify APRE's current valuation?
- •What does the current corporate distress warning mean for the reliability or interpretation of APRE's score?
Essential Investment Snapshot
Market Cap
$6.5M
P/E Ratio
-0.7
EPS
$-1.08
52-Week High
$1.69
52-Week Low
$0.55
Beta
1.63
Shares Outstanding
6.5M
Total Debt
$0
Dividend
No current dividend
Liquidation Value / Share
$5.88
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Strong downward momentum
Extreme movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for APRE
Detected from reported data — verify before acting.Share split detected
A recent SEC filing references a reverse stock split/share consolidation. Repeated reverse splits receive progressively harsher score ceilings.
Supporting sourceMAJOR RED FLAG: Reverse split proposed / authorized
A recent SEC filing discusses authorization, approval, or a proposal for a reverse stock split. This is treated as a major distress/listing-risk signal and caps Wall Street Score below 30 while pending.
Supporting filingCRITICAL: Going-concern warning
A recent SEC filing contains explicit going-concern language. Wall Street Score is capped at 15 until the distress condition is resolved in later filings.
Supporting filingCommunity Sentiment
0 active · 0 total callsNo personal call yet on APRE.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Focused pipeline of internally discovered synthetic lethality-based cancer therapeutics.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Biotechnology industry.
- −History of operating losses and expectation of continued losses.
- −Significant need for additional capital to fund clinical development.
- −Dependence on third-party clinical trial and manufacturing partners.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
Score changes will appear once more historical records are available.
Price vs. Value
Valuation unavailableCurrent Price
$0.51
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Large reported revenue change: +157.6%
Revenue changed sharply from 2023 to 2024. This can reflect a real business change, acquisition, divestiture, discontinued operations, restatement, or reporting-basis change. Compare the underlying filing before treating it as normal growth or decline.
TTM may combine quarters from before and after the event, so its trend can also be distorted.
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $0.00 | $1.5M | $583K | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | — | $0.00 | $9.4M | $7K | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | — | $0.00 | -$7.9M | $576K | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | — | $7.0M | $9.4M | $7.6M | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | — | $6.5M | $6.5M | $8.4M | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | — | $13.2M | $6.5M | $16.0M | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | — | -$12.6M | -$12.9M | -$14.3M | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | — | -$13.2M | -$14.3M | -$15.5M | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | — | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | — | -$12.6M | -$13.0M | -$14.3M | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | — | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | — | -$12.6M | -$13.0M | -$14.3M | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | — | $-1.93 | $-2.35 | $-3.95 | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 53.48M | 6.54M | 5.51M | 3.62M | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 53.48M | 6.54M | 5.51M | 3.62M | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$0
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.07
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
Not available
Cash Change
+149.4%
Margin Change
Not available
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Cash position grew
Potential Score Impact
Positive indicators included cash levels. Pressure indicators included revenue growth, EPS growth. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue declined 100.0%. EPS declined 86.8%. Cash increased 149.4%.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
6 historical recordsHistorical Score Chart
3 of 6 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyNews
Aprea Therapeutics to Host Pre-ESMO Virtual Panel on the State of WEE1 Inhibition in Precision Oncology
Aprea Therapeutics to Present Updated Interim Phase 1 Data on WEE1 Inhibitor APR-1051 in an Oral Presentation at 38th EORTC-NCI-AACR Symposium
Aprea Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference
Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs
Rumor Mill · APRE
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial